top of page

TAG's 2023 Pipeline Report: TB vaccines

Treatment Action Group (TAG) released the first TB chapter of its 2023 Pipeline Report offering a contextualized overview of TB vaccine candidates currently in clinical development. Tuberculosis Vaccines by Mike Frick is now available online as a downloadable PDF.

We cannot end TB without new and effective vaccines. Hearteningly, much progress has been made to that end: the pipeline is more robust than it ever has been, with tens of thousands of participants being recruited into Phase III trials across the globe. In 2023, some $600 million was pledged toward TB vaccine research, including $550 million from the Bill and Melinda Gates Foundation and the Wellcome Trust for a long-awaited Phase III trial of M72/AS01E slated to start in 2024. These commitments dwarf the woefully inadequate $143 million spent on TB vaccine R&D in 2022. Read more here.

37 views0 comments

Recent Posts

See All

Treat Action Group 2023 Pipeline Report

Their annual review provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB). View the full


bottom of page